日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pharmacokinetics and Macrophage Inhibitory Cytokine-1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT-232) in Fed and Fasted Healthy Subjects.

在饱腹和空腹健康受试者中,小鼠双微体 2 抑制剂 Navtemadlin (KRT-232) 的药代动力学和巨噬细胞抑制细胞因子-1 药效学

Wong Shekman, Krejsa Cecile, Lee Dana, Harris Anna, Simard Emilie, Wang Xiaohui, Allard Martine, Podoll Terry, O'Reilly Terry, Slatter J Greg

Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach

采用基于生理的药代动力学模型方法评价阿卡替尼及其活性代谢物ACP-5862的药物相互作用潜力

Zhou, Diansong; Podoll, Terry; Xu, Yan; Moorthy, Ganesh; Vishwanathan, Karthick; Ware, Joseph; Slatter, J Greg; Al-Huniti, Nidal

Pharmacokinetics, Biotransformation, and Excretion of [(14)C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis

在接受血液透析的慢性肾脏病患者中,单次静脉注射微量示踪剂[(14)C]依替卡西肽(AMG 416)后的药代动力学、生物转化和排泄情况

Subramanian, Raju; Zhu, Xiaochun; Hock, M Benjamin; Sloey, Bethlyn J; Wu, Benjamin; Wilson, Sarah F; Egbuna, Ogo; Slatter, J Greg; Xiao, Jim; Skiles, Gary L

Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment

对全人源抗PCSK9 IgG2单克隆抗体Evolocumab(AMG 145)在肝功能受损患者中的疗效评价

Gibbs, John P; Slatter, J Greg; Egbuna, Ogo; Geller, Michelle; Hamilton, Lisa; Dias, Clapton S; Xu, Ren Y; Johnson, Jessica; Wasserman, Scott M; Emery, Maurice G

Therapeutic protein drug-drug interactions: navigating the knowledge gaps-highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA workshop

治疗性蛋白质药物相互作用:弥合知识鸿沟——2012年AAPS NBC圆桌会议和IQ联盟/FDA研讨会要点

Kenny, Jane R; Liu, Maggie M; Chow, Andrew T; Earp, Justin C; Evers, Raymond; Slatter, J Greg; Wang, Diane D; Zhang, Lei; Zhou, Honghui